Showing results (1321-1330 of 1,431) with videos related to
Sort By:
Pageof 144
The Lancet. Oncology|June 22, 2014
Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trialBradley J Monk, Andrés Poveda, Ignace Vergote, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomesLucy Haggstrom, Yeh Chen Lee, Clare Scott, et al.Journal of the American Academy of Dermatology|June 15, 2026
Progression of skin-limited pediatric-onset discoid lupus erythematosus to diagnosis of systemic lupus erythematosus: results of a multicenter, retrospective cohort studyL M Arkin, K A Buhr, S P Ardoin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2020
Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup TrialTim Eisen, Eleni Frangou, Bhavna Oza, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 30, 2020
Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86)Neesha C Dhani, Hal W Hirte, Lisa Wang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 14, 2021
Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II StudyKathleen N Moore, Setsuko K Chambers, Erika P Hamilton, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 23, 2017
Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular CharacterizationStephanie Lheureux, Zhongwu Lai, Brian A Dougherty, et al.Journal of Medicinal Chemistry|September 9, 2011
Discovery of (+)-N-(3-aminopropyl)-N-[1-(5-benzyl-3-methyl-4-oxo-[1,2]thiazolo[5,4-d]pyrimidin-6-yl)-2-methylpropyl]-4-methylbenzamide (AZD4877), a kinesin spindle protein inhibitor and potential anticancer agentMaria-Elena Theoclitou, Brian Aquila, Michael H Block, et al.Journal of Interventional Cardiac Electrophysiology : an International Journal of Arrhythmias and Pacing|July 2, 2021
A prospective multi-site registry of real-world experience of catheter ablation for treatment of symptomatic paroxysmal and persistent atrial fibrillation (Real-AF): design and objectivesAllyson L Varley, Omar Kreidieh, Brigham E Godfrey, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|June 9, 2021
Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3Andrew R Clamp, Domenica Lorusso, Amit M Oza, et al.Pageof 144